axitinib + FOLFOX

Axitinib + FOLFOX is a **combination regimen** consisting of axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors (VEGFR 1, 2, and 3), together with the FOLFOX chemotherapy regimen, which includes folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin. The combination targets tumor angiogenesis and directly cytotoxic effects on cancer cells. Axitinib acts by blocking VEGF-mediated signaling to inhibit angiogenesis in tumors, while FOLFOX impairs DNA replication, repair, and cell division in rapidly dividing cancer cells. This regimen has been investigated primarily for the treatment of advanced gastrointestinal cancers, particularly metastatic colorectal cancer, in phase I and II trials. The combination has been shown to be generally well tolerated, with adverse events manageable and pharmacokinetic interactions absent[1][3][5].

Other names

axitinib plus FOLFOXaxitinib + FOLFOXaxitinib combined with FOLFOX